WO2010088000A3 - Composés antifibrotiques et leurs utilisations - Google Patents
Composés antifibrotiques et leurs utilisations Download PDFInfo
- Publication number
- WO2010088000A3 WO2010088000A3 PCT/US2010/000287 US2010000287W WO2010088000A3 WO 2010088000 A3 WO2010088000 A3 WO 2010088000A3 US 2010000287 W US2010000287 W US 2010000287W WO 2010088000 A3 WO2010088000 A3 WO 2010088000A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compounds
- antifibrotic compounds
- antifibrotic
- subclasses
- classes
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La présente invention concerne des composés ayant les formules (I), (II) et (III) : F et leurs dérivés pharmaceutiquement acceptables, comme il est décrit généralement et par classes et sous-classes ici, et elle concerne en outre des compositions pharmaceutiques les contenant, et des procédés pour les utiliser pour le traitement de l'un quelconque de nombreux états et maladies impliquant une fibrose et pour lesquels une activité antifibrotique est bénéfique.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20661509P | 2009-02-02 | 2009-02-02 | |
US61/206,615 | 2009-02-02 | ||
US21474409P | 2009-04-28 | 2009-04-28 | |
US61/214,744 | 2009-04-28 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2010088000A2 WO2010088000A2 (fr) | 2010-08-05 |
WO2010088000A3 true WO2010088000A3 (fr) | 2011-04-07 |
Family
ID=42396268
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2010/000287 WO2010088000A2 (fr) | 2009-02-02 | 2010-02-02 | Composés antifibrotiques et leurs utilisations |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2010088000A2 (fr) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8883819B2 (en) | 2011-09-01 | 2014-11-11 | Irm Llc | Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension |
CA2857344C (fr) | 2011-12-21 | 2019-02-12 | Novira Therapeutics, Inc. | Agents antiviraux de l'hepatite b |
JP6152389B2 (ja) * | 2012-01-26 | 2017-06-21 | アンジオン バイオメディカ コーポレーション | 抗線維化化合物及びその使用 |
SG10201605291WA (en) | 2012-08-28 | 2016-08-30 | Janssen Sciences Ireland Uc | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b |
HUE034820T2 (en) | 2013-02-28 | 2018-02-28 | Janssen Sciences Ireland Uc | Sulphamoyl arylamides and their use as medicaments for the treatment of hepatitis B |
US9073921B2 (en) | 2013-03-01 | 2015-07-07 | Novartis Ag | Salt forms of bicyclic heterocyclic derivatives |
US8993771B2 (en) | 2013-03-12 | 2015-03-31 | Novira Therapeutics, Inc. | Hepatitis B antiviral agents |
EA027068B1 (ru) | 2013-04-03 | 2017-06-30 | Янссен Сайенсиз Айрлэнд Юси | Производные n-фенилкарбоксамида и их применение в качестве лекарственных препаратов для лечения гепатита b |
JO3603B1 (ar) | 2013-05-17 | 2020-07-05 | Janssen Sciences Ireland Uc | مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي |
TR201807090T4 (tr) | 2013-07-25 | 2018-06-21 | Janssen Sciences Ireland Uc | Glioksamid sübstitüeli pirrolamid deriveleri ve bunun hepatitin tedavisine yönelik ilaçlar olarak kullanımı. |
WO2015059212A1 (fr) | 2013-10-23 | 2015-04-30 | Janssen R&D Ireland | Dérivés de carboxamide et leur utilisation en tant que médicaments pour le traitement de l'hépatite b |
US9181288B2 (en) | 2014-01-16 | 2015-11-10 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
US9169212B2 (en) | 2014-01-16 | 2015-10-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
US10392349B2 (en) | 2014-01-16 | 2019-08-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
AU2015214096B2 (en) | 2014-02-05 | 2021-02-11 | Novira Therapeutics, Inc. | Combination therapy for treatment of HBV infections |
CN110483484A (zh) | 2014-02-06 | 2019-11-22 | 爱尔兰詹森科学公司 | 氨磺酰基吡咯酰胺衍生物及其作为药物用于治疗乙型肝炎的用途 |
US9400280B2 (en) | 2014-03-27 | 2016-07-26 | Novira Therapeutics, Inc. | Piperidine derivatives and methods of treating hepatitis B infections |
JP2018510159A (ja) | 2015-03-19 | 2018-04-12 | ノヴィラ・セラピューティクス・インコーポレイテッド | アゾカン及びアゾナン誘導体及びb型肝炎感染症の治療法 |
US10875876B2 (en) | 2015-07-02 | 2020-12-29 | Janssen Sciences Ireland Uc | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
CA3000197A1 (fr) | 2015-09-29 | 2017-04-06 | Novira Therapeutics, Inc. | Formes cristallines d'un agent antiviral de l'hepatite b |
EP3848026A1 (fr) | 2016-04-15 | 2021-07-14 | Novira Therapeutics Inc. | Combinaisons et procédés comprenant un inhibiteur d'assemblage de capside |
MA52019A (fr) | 2018-03-14 | 2021-01-20 | Janssen Sciences Ireland Unlimited Co | Schéma posologique de modulateur d'assemblage de capside |
JP2022521081A (ja) | 2019-02-22 | 2022-04-05 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | Hbv感染若しくはhbv誘導性疾患の治療において有用なアミド誘導体 |
CN113795486A (zh) | 2019-05-06 | 2021-12-14 | 爱尔兰詹森科学公司 | 用于治疗hbv感染或hbv诱发的疾病的酰胺衍生物 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004063330A2 (fr) * | 2003-01-06 | 2004-07-29 | Osi Pharmaceuticals, Inc. | Composes de (2-carboxamido) (3-amino) thiophene |
US20050154014A1 (en) * | 2003-01-06 | 2005-07-14 | Jason Bloxham | (2-carboxamido)(3-amino) thiophene compounds |
US20060074082A1 (en) * | 2004-09-17 | 2006-04-06 | Arlindo Castelhano | (Arylamidoaryl)cyanoguanidine compounds |
WO2006070878A1 (fr) * | 2004-12-28 | 2006-07-06 | Astellas Pharma Inc. | Derive d'acide carboxylique ou sel de ce derive |
-
2010
- 2010-02-02 WO PCT/US2010/000287 patent/WO2010088000A2/fr active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004063330A2 (fr) * | 2003-01-06 | 2004-07-29 | Osi Pharmaceuticals, Inc. | Composes de (2-carboxamido) (3-amino) thiophene |
US20050154014A1 (en) * | 2003-01-06 | 2005-07-14 | Jason Bloxham | (2-carboxamido)(3-amino) thiophene compounds |
US20060074082A1 (en) * | 2004-09-17 | 2006-04-06 | Arlindo Castelhano | (Arylamidoaryl)cyanoguanidine compounds |
WO2006070878A1 (fr) * | 2004-12-28 | 2006-07-06 | Astellas Pharma Inc. | Derive d'acide carboxylique ou sel de ce derive |
Also Published As
Publication number | Publication date |
---|---|
WO2010088000A2 (fr) | 2010-08-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2010088000A3 (fr) | Composés antifibrotiques et leurs utilisations | |
WO2011153192A3 (fr) | Inhibiteurs des cytochromes p450 et leurs utilisations | |
WO2011127333A3 (fr) | Composés pour le traitement d'une maladie, pour l'administration, et pour des compositions pharmaceutiques | |
WO2013112959A8 (fr) | Composés antifibrotiques et leurs utilisations | |
WO2010084115A3 (fr) | Agents antiviraux | |
MX2011012122A (es) | Derivados de tiofeno. | |
WO2012116290A3 (fr) | Stéroïdes neuroactifs substitués par 17(20)-z-vinylcyano, promédicaments de ceux-ci et procédés de traitement les utilisant | |
AU2012243329A8 (en) | 5-substituted iminothiazines and their mono-and dioxides as BACE inhibitors,compositions,and their use | |
MX2008016134A (es) | Derivados de fenol para el tratamiento de enfermedades respiratorias. | |
WO2009109618A3 (fr) | Nouveaux dérivés de 1-benzyl-3-hydroxyméthylindazole et leur utilisation dans le traitement des maladies basées sur l’expression de mcp-1, cx3cr1 et p40 | |
GEP20186880B (en) | 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease | |
WO2009109616A3 (fr) | Nouveaux dérivés de 1-benzyl-3-hydroxyméthylindazole et leur utilisation dans le traitement des maladies basées sur l'expression de mcp-1, cx3cr1 et p40 | |
MX2012000275A (es) | Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal. | |
MX2009013501A (es) | Compuestos piperidinicos y sus usos. | |
WO2009109654A8 (fr) | Nouveaux dérivés de 1-benzyl-3-hydroxyméthylindazole et leur utilisation dans le traitement des maladies basées sur l’expression de mcp-1 et cx3cr1 | |
WO2009041663A1 (fr) | Agent destiné à la prévention et/ou au traitement de maladies cutanées | |
WO2011097946A8 (fr) | Composés oxazolidinone contenant deux cycles fusionnés, procédé de préparation associé et utilisation associée | |
WO2012135615A3 (fr) | Enopeptines, utilisations de celles-ci, et procédés de synthèse de celles-ci | |
WO2012168885A9 (fr) | Bisacodyle et ses analogues en tant que médicaments pour le traitement du cancer | |
MX362830B (es) | Agente terapeutico o profilactico para enfermedades del tracto biliar. | |
WO2013019091A3 (fr) | Composé d'inhibition de la 11β-hydroxystéroïde déshydrogénase de type 1, et composition pharmaceutique le comprenant | |
WO2012128582A3 (fr) | Composé capable d'inhiber la 11-bêta-hydroxystéroïde déshydrogénase de type 1 humaine et composition pharmaceutique en contenant | |
MX2012013879A (es) | Derivados de hidroxipiridona, composiciones farmceuticas de los mismos y su uso terapeutico para tratar enfermedades proliferativas. | |
WO2011009714A3 (fr) | Dérivés de sel de benzoquinolizinium comme agents anti-cancéreux | |
WO2010121675A3 (fr) | Thiazolyl-benzimidazoles |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10736165 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 10736165 Country of ref document: EP Kind code of ref document: A2 |